OncoMatch/Clinical Trials/NCT04024761
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Is NCT04024761 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including CIML NK and Fludarabine for acute myeloid leukemia.
Treatment: CIML NK · Fludarabine · Cyclophosphamide — This research study is studying cytokine induced memory-like natural killer (CIML NK) cells combined with IL-2 in adult patients (18 years of age or older) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) who relapse after haploidentical hematopoietic cell transplantation (haplo-HCT) or HLA matched stem cells. This study will also study CIML NK cell infusion combined with IL-2 in pediatric patients (12 years of age or older) with AML, MDS, JMML who relapse after stem cell transplantation using HLA-matched related donor or related donor haploidentical stem cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: stem cell transplant — allogeneic
at least 2 months after stem cell transplantation
Cannot have received: Donor Lymphocyte Infusion
Exception: DLI given >8 weeks before CIML NK infusion and did not result in GVHD requiring systemic treatment is not an exclusion criterion
Prior history of Donor Lymphocyte Infusion (DLI) within 8 weeks of CIML NK infusion
Lab requirements
Kidney function
Serum creatinine ≤2.0mg/dL
Liver function
Total bilirubin: ≤1.5 x institutional ULN (except Gilbert's or disease-related hemolysis, then <3 x ULN); AST(SGOT)/ALT(SGPT): ≤3 x institutional ULN
Cardiac function
O2 saturation: ≥90% on room air; LVEF >40%
Adequate organ function within 2 weeks of NK cell infusion as defined below: Total bilirubin: ≤1.5 x institutional upper limit of normal (ULN) (except Gilbert's or disease-related hemolysis, then <3 x ULN); AST(SGOT)/ALT(SGPT): ≤3 x institutional ULN; Serum creatinine ≤2.0mg/dL; O2 saturation: ≥90% on room air; LVEF >40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Boston Children's Hospital · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify